Rezex Medical

Pat Black CEO, brings twenty plus years of leadership experience in medical product development. She has $500MM NPV in product launches and has worked exclusively with startups for the last 4 years. Reza Rajebi, MD, CMO has expertise in interventional radiology and clinical research, he has performed thousands of arterial endovascular procedures. In addition our advisory board brings a dept of both business and IR leadership.

Rezex Medical is developing a large-bore vascular closure device to optimize complex surgical workflows and decrease complication rates. Closing large bore vascular access is a challenge with limited on market solutions. Arterial Peripheral Cardiac Procedures using large bore devices are the fastest growing segment of the cardiovascular market. The global market estimate is $440M per year, it is expected to exceed $700M by 2024.

While small bore closure during an endovascular procedure is now standard, closing the large bore vascular access creates a significant challenge. The bleeding complication rate, including life-threatening hemorrhage, in these procedures after surgical cutdown due to complications is currently over 17%, which dramatically impacts patient safety and increases healthcare costs.

Endovascular cardiac and aortic minimally invasive procedures comprise the fastest growing segment of the cardiovascular market and drive the worldwide market for large-bore vascular closure devices. The current closure device market options are limited leading to expensive, complex, time and labor-intensive workflows with multiple devices. Technologies to circumvent burnout for cardiovascular teams are also a growing market need.

Rezex-CLZ will solve the growing vascular closure challenge by allowing a user to perform closure of a large bore common femoral artery access site. It will promote healing, decreasing clotting, bleeding, and infection. Using a single device will lower costs and reduce time to ambulation and discharge.

Company’s Keywords: